Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate—a novel nonpeptide IL-6 receptor antagonist
Authors:
- Mun-Chual RhoMRMun-Chual Rho
- Masahiko HayashiMHMasahiko Hayashi
- 1 October 2004
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 323 (3) , 1096-1102
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 28 references indexed in Scilit:
- Inhibitory Effects of Bufadienolides on Interleukin-6 in MH-60 CellsJournal of Natural Products, 2004
- Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trialArthritis & Rheumatism, 2002
- Biological Activity of a Novel Nonpeptide Antagonist to the Interleukin-6 Receptor 20 S,21-Epoxy-resibufogenin-3-formateThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Parathyroid hormone related protein and interleukin-6 mRNA expression in larynx and renal cell carcinomas from normocalcaemic and hypercalcaemic patients.Journal of Clinical Pathology, 1995
- Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regionsMolecular Immunology, 1994
- Association of Transcription Factor APRF and Protein Kinase Jak1 with the Interleukin-6 Signal Transducer gp130Science, 1994
- Interleukin-11Leukemia & Lymphoma, 1994
- Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.Journal of Clinical Investigation, 1993
- Current Concepts of B Cell ModulationInternational Reviews of Immunology, 1989
- Inhibition of Human Immunodeficiency Virus Type I Reverse Transcriptase by Suramin-related CompoundsJournal of General Virology, 1987